3 64

Cited 4 times in

Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study.

Authors
 Soohyeon Lee ; Sang Hyun Yoon ; Hye Jin Choi ; Kwang-Hyub Han ; Sang Hoon Ahn ; Do Young Kim ; Jun Yong Park 
Citation
 Investigational New Drugs, Vol.30(3) : 1150~1157, 2012 
Journal Title
 Investigational New Drugs 
ISSN
 0167-6997 
Issue Date
2012
Abstract
BACKGROUND: Prior to the 2008 advent of sorafenib, traditional cytotoxic agents were the therapeutic mainstay for patients with advanced hepatocellular carcinoma (HCC). We thus undertook a clinical study of sorafinib and conventional cytotoxic therapy for HCC, comparing efficacy and safety. METHODS: From January, 2002 to December, 2009, 173 patients with unresectable HCC were reviewed retrospectively. Among them, 44 (25.4%) had been treated with sorafenib, and the remainder had received cytotoxic therapy (CTX). We evaluated objective response rate (ORR), progression free survival (PFS), overall survival (OS), and toxicity profiles. RESULTS: Median OS of sorafinib was 23.0 weeks (95% CI, 8.1-37.9) vs 43.6 weeks (95% CI, 34.0-53.2) for CTX. Likewise, median PFS was 11.1 weeks (95% CI, 6.5-15.8) vs 12.4 weeks (95% CI, 8.1-16.7) for sorafenib and CTX, respectively. Neither parameter differed significantly (OS, p = 0.105; PFS, p = 0.496). ORR and disease control rate for sorafenib were 2.3% and 52.3% vs 6.2% and 43.4% for CTX. CTX-treated patients experienced more Grade 3/4 neutropenia (19.7% vs 0% for sorafenib), while sorafenib therapy was more often linked to dermatologic toxicities (all grades), such as hand-foot skin reaction, rash, and pruritus. CONCLUSION: Although sorafenib has become the treatment of choice for advanced HCC, there are still unsettled issues regarding the optimal use of sorafenib. Our analysis indicates that conventional CTX can be another option of treatment for advanced HCC. To improve clinical outcomes, further prospective investigations which define the role of CTX are needed.
URI
http://ir.ymlib.yonsei.ac.kr/handle/22282913/90570
DOI
10.1007/s10637-011-9634-4
Appears in Collections:
1. 연구논문 > 1. College of Medicine > Dept. of Internal Medicine
Yonsei Authors
사서에게 알리기
  feedback
Link
 http://link.springer.com/article/10.1007%2Fs10637-011-9634-4
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse